EJMI. 2021; 5(2): 274-282 | DOI: 10.14744/ejmi.2021.30532

ICE Regimen in Adult Advanced/Relapsed Soft Tissue Sarcoma Patients; is it More Effective in Early Use? Retrospective Analysis of Single Center Study

Zeynep Oruc¹, Yasin Sezgin¹, Ogur Karhan¹, Senar Ebinc¹, Muhammet Ali Kaplan¹, Mehmet Kucukoner¹, Zuhat Urakci¹, Idris Oruc², Abdurrahman Isikdogan^1
1Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakir, Turkey, ²Department of Nephrology, Dicle University,Faculty of Medicine, Diyarbakir, Turkey

Objectives: To analyze the efficacy and tolerability of the ICE regimen and prognostic factors for survival in patients with advanced or relapsed soft tissue sarcomas treated with the ICE regimen (ifosfamide, carboplatin and etoposide). Methods: The records of 28 patients diagnosed with advanced or relapsed soft tissue sarcoma who were treated with the ICE regimen at our center between 2008 and 2020, were evaluated retrospectively. Results: The most common histopathological subtype were pleomorphic sarcoma (9/32.1%). After a median follow-up duration of 8 months, the median PFS and OS were 6 months (95% confidence interval (CI), 3.6–8.3) and 9.3 months (95% CI, 4.7–13.9), respectively. A multivariate analysis for overall survival revealed the ICE treatment line (HR:4.8, 95% Cl 1.7–12.8, p: 0.002), tumor site (HR: 0.12, 95% Cl 0.03–0.4, p: 0.001) and response to ICE regimen (HR: 0.09, 95% Cl 0.01–0.49, p: 0.005) to be independent prognostic factors. The group that received 1–2 chemotherapy regimens prior to the ICE regimen recorded better OS than the group received more than two chemotherapy regimens (22.8 months vs 5 months, p: 0.006). Conclusion: The ICE regimen may be particularly effective when used for early treatment after doxorubicin-based therapy in patients with advanced or relapsed soft tissue sarcomas. Keywords: Chemotherapy, ICE regimen; soft tissue sarcoma

---

Cite This Article

Oruc Z, Sezgin Y, Karhan O, Ebinc S, Kaplan M, Kucukoner M, Urakci Z, Oruc I, Isikdogan A. ICE Regimen in Adult Advanced/Relapsed Soft Tissue Sarcoma Patients; is it More Effective in Early Use? Retrospective Analysis of Single Center Study. EJMI. 2021; 5(2): 274-282

Corresponding Author: Zeynep Oruc

Full Text PDF PDF Download